Hormone replacement therapy and cancer mortality in women with 17 site-specific cancers: a cohort study using linked medical records

TL;DR

This study found no increased cancer-specific mortality in women with various cancers (excluding breast) who used hormone replacement therapy.

Contribution

The study provides new evidence on the safety of HRT in women with 17 different cancers, excluding breast cancer.

Findings

HRT use was not associated with higher cancer-specific mortality across 17 cancer sites.

Common cancers like lung, colorectal, and melanoma showed no increased mortality with HRT use.

Only 7% of patients used systemic HRT after their cancer diagnosis.

Abstract

There is limited evidence on the safety of Hormone Replacement Therapy (HRT) in women with cancer. Therefore, we systematically examined HRT use and cancer-specific mortality in women with 17 site-specific cancers.

Women newly diagnosed with 17 site-specific cancers from 1998 to 2019, were identified from general practitioner (GP) records, hospital diagnoses or cancer registries in Scotland, Wales and England. Breast cancer patients were excluded because HRT is contraindicated in breast cancer patients. The primary outcome was time to cancer-specific mortality. Time-dependent Cox regression models were used to calculate adjusted hazard ratios (HR) and 95% confidence intervals (95% CIs) for cancer-specific mortality by systemic HRT use.

The combined cancer cohorts contained 182,589 women across 17 cancer sites. Overall 7% of patients used systemic HRT after their cancer diagnosis. There was no evidence that HRT users, compared with non-users, had higher cancer-specific mortality at any cancer site. In particular, no increase was observed in common cancers including lung (adjusted HR = 0.98 95% CI 0.90, 1.07), colorectal (adjusted HR = 0.79 95% CI 0.70, 0.90), and melanoma (adjusted HR = 0.77 95% CI 0.58, 1.02).

We observed no evidence of increased cancer-specific mortality in women with a range of cancers (excluding breast) receiving HRT.

Figures